20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Up 613.4% in May

20/20 Biolabs Inc (NASDAQ:AIDX) was the recipient of a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 128,775 shares, a growth of 613.4% from the May 14th total of 18,050 shares. Based on an average trading volume of 1,125,074 shares, the short-interest ratio is presently 0.1 days. Approximately 1.2% of the shares of the company are short sold.

20/20 Biolabs Trading Down 0.7%

Shares of AIDX stock traded down $0.01 during trading on Thursday, hitting $0.86. The company had a trading volume of 10,724 shares, compared to its average volume of 331,620. 20/20 Biolabs has a 52 week low of $0.78 and a 52 week high of $50.00. The business’s 50-day simple moving average is $1.42.

20/20 Biolabs (NASDAQ:AIDX) last released its earnings results on Wednesday, May 20th. The company reported ($0.28) EPS for the quarter. The company had revenue of $0.35 million during the quarter.

Wall Street Analyst Weigh In

Several research firms recently commented on AIDX. Weiss Ratings initiated coverage on 20/20 Biolabs in a research note on Thursday, May 14th. They issued a “sell (e-)” rating on the stock. Wall Street Zen raised 20/20 Biolabs to a “hold” rating in a research report on Saturday, March 14th. Finally, Maxim Group initiated coverage on 20/20 Biolabs in a report on Monday, May 11th. They issued a “buy” rating and a $5.00 price objective for the company. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.00.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.